Consensus statement: Recommendations for the management of metabolic bone disease in human immunodeficiency virus patients;Documento de consenso: Recomendaciones para el manejo de la enfermedad ósea metabólica en pacientes con virus de la inmunodeficiencia humana

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 32, Issue 4, 2014, Pages 250-258

  Martínez, Esteban ^a   Jódar Gimeno, Esteban ^b   Reyes García, Rebeca ^c   Carpintero, Pedro ^d   Casado, José Luis ^e   Del Pino Montes, Javier ^f   Domingo Pedrol, Pere ^g   Estrada, Vicente ^h   Maalouf, Jorge ^g   Negredo, Eugenia ⁱ   Ocampo, Antonio ^j   Muñoz Torres, Manuel ^k  

^a HOSPITAL CLÍNIC   (Spain)

^b Hospital Universitario Quirón   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^h HOSPITAL CLÍNICO SAN CARLOS   (Spain)

ⁱ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^j UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^k HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

more..

Author keywords

Bone metabolism; Human immunodeficiency virus; Osteoporosis; Recommendations; Vitamin D

Indexed keywords

ARTICLE; BONE METABOLISM; CONSENSUS; EVALUATION STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MEDICAL SOCIETY; METABOLIC BONE DISEASE; SCORING SYSTEM; SYSTEMATIC REVIEW; ALGORITHM; BONE DISEASES, METABOLIC; COMPLICATION; CONSENSUS DEVELOPMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OSTEOPOROSIS; PRACTICE GUIDELINE; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE;

ALGORITHMS; BONE DISEASES, METABOLIC; HIV INFECTIONS; HUMANS; OSTEOPOROSIS;

EID: 84898548937     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2013.07.008     Document Type: Article

References (72)

1. Lundgren J. European AIDS Clinical Society Guidelines: Prevention and management of non-infectious co-morbidities in HIV [consultado 28 May 2013]. Disponible en: http://www.europeanaidsclinicalsociety.org/Guidelines/G2-p52.htm
2. G.A. McComsey, P. Tebas, E. Shane, M.T. Yin, E.T. Overton, and J.S. Huang et al. Bone disease in HIV infection: A practical review and recommendations for HIV care providers Clin Infect Dis 51 2010 937 946
3. D. Atkins, D. Best, P.A. Briss, M. Eccles, Y. Falck-Ytter, and S. Flottorp et al. Grading quality of evidence and strength of recommendations BMJ 328 2004 1490
4. ® tool, the WHO algorithm to predict osteoporotic fractures: The first analysis of its discriminative and predictive ability in the Spanish FRIDEX cohort BMC Musculoskelet Disord 13 2012 204
5. L. Gazzola, L. Comi, A. Savoldi, L. Tagliabue, A. del Sole, and L. Pietrogrande et al. Use of the FRAX equation as first-line screening of bone metabolism alteration in the HIV-infected population J Infect Dis 202 2010 330 331
6. J. Pepe, A.M. Isidori, M. Falciano, G. Iaiani, A. Salotti, and D. Diacinti et al. The combination of FRAX and Ageing Male Symptoms scale better identifies treated HIV males at risk for major fracture Clin Endocrinol (Oxf) 77 2012 672 678
7. J.A. Kanis, E.V. McCloskey, H. Johansson, C. Cooper, R. Rizzoli, and J.Y. Reginster Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporos Int 24 2013 23 57
8. R. Güerri-Fernandez, P. Vestergaard, C. Carbonell, H. Knobel, F.F. Avilés, and A. Castro et al. HIV infection is strongly associated with hip fracture risk, independently of age, gender and co-morbidities: A population-based cohort study J Bone Miner Res 28 2013 1259 1263
9. Daria G, Gianizza M, Porcelli T, Albini L, Foca E, Castelli F, et al. Bone Mineral Density and Prevalence of Asymptomatic Vertebral Fractures in HIV+ Patients on cART. 20th Conference on Retroviruses and Oportunistic Infections 2013, abstract 822 [consultado 5 Dic 2012]. Disponible en: http://www. retroconference.org/2013b/Abstracts/47568.htm
10. A. Diez-Perez, J.D. Adachi, D. Agnusdei, J.P. Bilezikian, J.E. Compston, and S.R. Cummings et al. IOF CSA Inadequate Responders Working Group. Treatment failure in osteoporosis Osteoporos Int 23 2012 2769 2774
11. N.B. Watts, R.A. Adler, J.P. Bilezikian, M.T. Drake, R. Eastell, and E.S. Orwoll et al. Endocrine Society. Osteoporosis in men: An Endocrine Society clinical practice guideline J Clin Endocrinol Metab 97 2012 1802 1822
12. E. Negredo, A. Bonjoch, M. Gómez-Mateu, C. Estany, J. Puig, and N. Perez-Alvarez et al. Time of progression to osteopenia/osteoporosis in chronically HIV-infected patients: screening DXA scan PLoS One 7 2012 e46031
13. M. Gunnes, E.H. Lehmann, D. Mellstrom, and O. Johnell The relationship between anthropometric measurements and fractures in women Bone 19 1996 407 413
14. J.A. Womack, J.L. Goulet, C. Gibert, C.A. Brandt, M. Skanderson, and B. Gulanski et al. Veterans Aging Cohort Study Project Team. Physiologic frailty and fragility fracture in HIV-infected male veterans Clin Infect Dis 56 2013 1498 1504
15. M.F. Holick, N.C. Binkley, H.A. Bischoff-Ferrari, C.M. Gordon, D.A. Hanley, and R.P. Heaney et al. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline J Clin Endocrinol Metab 96 2011 1911 1930
16. V. Walker Harris, and T.T. Brown Bone loss in the HIV-infected patient: Evidence, clinical implications, and treatment strategies J Infect Dis 205 Suppl 3 2012 S391 S398
17. E.T. Overton, and M.T. Yin The rapidly evolving research on vitamin D among HIV-infected populations Curr Infect Dis Rep 13 2011 83 93
18. C.J. Van den Bout-van den Beukel, L. Fievez, M. Michels, F.C. Sweep, A.R. Hermus, and M.E. Bosch et al. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: Effects of antiretroviral therapy AIDS Res Hum Retroviruses 24 2008 1.375 1.382
19. A.R. Eckard, S.E. Judd, T.R. Ziegler, A.F. Camacho-Gonzalez, A.M. Fitzpatrick, and G.R. Hadley et al. Risk factors for vitamin D deficiency and relationship with cardiac biomarkers, inflammation and immune restoration in HIV infected youth Antivir Ther 17 2012 1069 1078
20. R.D. Crutchely, J. Gathe, C. Mayberry, A. Trieu, S. Abughosh, and K.W. Garey Risk factors for vitamin D deficiency in HIV-infected patients in the south central United States AIDS Res Hum Retroviruses 28 2012 454 459
21. European AIDS Clinical Society. European AIDS Clinical Society guidelines: Prevention and management of non-infectious co-morbidities in HIV. October 11 [consultado 5 Dic 2012]. Disponible en: http://www. europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EACSGuidelinesv6. 0-English.pdf
22. A.C. Ross, J.E. Manson, S.A. Abrams, J.F. Aloia, P.M. Brannon, and S.K. Clinton et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know J Clin EndocrinolMetab 96 2011 53 58
23. M. Cervero, J.L. Agud, C. García-Lacalle, V. Alcázar, R. Torres, and J.J. Jusdado et al. Prevalence of vitamin D deficiency and its related risk factor in a Spanish cohort of adult HIV-infected patients: Effects of antiretroviral therapy AIDS Res Hum Retroviruses 28 2012 963 971
24. B. Terrier, F. Carrat, G. Geri, S. Pol, L. Piroth, and P. Halfon et al. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis J Hepatol 55 2011 756 761
25. N. Napoli, J. Thompson, R. Civitelli, and R.C. Armamento-Villareal Effects of dietary calcium compared with calcium supplements on estrogen metabolism and bone mineral density Am J Clin Nutr 85 2007 1428 1433
26. E. Jódar Gimeno, J. González Macías, P. Aguado Acín, J.M. Quesada Gómez, E. Cáceres, and G. Nocea Perspectivas actuales del papel de la vitamina D y del calcio en el cuidado del paciente con osteoporosis: discusión de un panel de expertos Rev Osteoporos Metab Miner 2 2010 63 74
27. T.E. Howe, B. Shea, L.J. Dawson, F. Downie, A. Murray, and C. Ross et al. Exercise for preventing and treating osteoporosis in postmenopausal women Cochrane Database Syst Rev 7 2011 Jul 6 CD000333
28. L.D. Gillespie, M.C. Robertson, W.J. Gillespie, C. Sherrington, S. Gates, and L.M. Clemson et al. Interventions for preventing falls in older people living in the community Cochrane Database Syst Rev 9 2012 Sep 12 CD007146
29. J.D. Lundgren, M. Battegay, G. Behrens, S. de Wit, G. Guaraldi, and C. Katlama et al. EACS Executive Committee European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV HIV Med 9 2008 72 81
30. D.B. Maurel, N. Boisseau, C.L. Benhamou, and C. Jaffre Alcohol and bone: Review of dose effects and mechanisms Osteoporos Int 23 2012 1 16
31. V. Yoon, N.M. Maalouf, and K. Sakhaee The effects of smoking on bone metabolism Osteoporos Int 23 2012 2081 2092
32. M. Rodriguez, B. Daniels, S. Gunawardene, and G.K. Robbins High frequency of vitamin D deficiency in ambulatory HIV-positive patients AIDS Res Hum Retroviruses 25 2009 9 14
33. C.B. Stephensen, G.S. Marquis, L.A. Kruzich, S.D. Douglas, G.M. Aldrovandi, and C.M. Wilson Vitamin D status in adolescents and young adults with HIV infection Am J Clin Nutr 83 2006 1135 1141
34. M. Etminani-Esfahani, H. Khalili, S. Jafari, A. Abdollahi, and S. Dashti-Khavidaki Effects of vitamin D supplementation on the bone specific biomarkers in HIV infected individuals under treatment with efavirenz BMC Res Notes 5 2012 204
35. P. Peris, A. Martínez-Ferrer, A. Monegal, M.J. Martínez de Osaba, A. Muxi, and N. Guañabens 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis Bone 51 2012 54 58
36. A.S. Carmel, A. Shieh, H. Bang, and R.S. Bockman The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥ 33 ng/ml Osteoporos Int 23 2012 2479 2487
37. N.M. Maalouf, H.J. Heller, C.V. Odvina, P.J. Kim, and K. Sakhaee Bisphosphonate-inducedhypocalcemia: Report of 3 cases and review of literature Endocr Pract 12 2006 48 53
38. H. Cejtin, A. Kalinowski, P. Bacchetti, R.N. Taylor, D.H. Watts, and S. Kim et al. Effects of human immunodeficiency virus on protracted amenorrhea and ovarian dysfunction Obstet Gynecol 108 2006 1423 1431
39. E.E. Schoenbaum, D. Hartel, Y. Lo, A.A. Howard, M. Floris-Moore, and J.H. Arnsten et al. HIV infection, drug use, and onset of natural menopause Clin Infect Dis 41 2005 1517 1524
40. C.N. Mircea, M.E. Lujan, and R.A. Pierson Metabolic fuel and clinical implications for female reproduction J Obstet Gynaecol Can 29 2007 887 902
41. P. Rietschel, C. Corcoran, T. Stanley, N. Basgoz, A. Klibanski, and S. Grinspoon Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy Clin Infect Dis 31 2000 1240 1244
42. R.R. Kalyani, S. Gavini, and A.S. Dobs Male hypogonadism in systemic disease Endocrinol Metab Clin North Am 36 2007 333 348
43. V. Rochira, L. Zirilli, G. Orlando, D. Santi, G. Brigante, and C. Diazzi et al. Premature decline of serum total testosterone in HIV-infected men in the HAART-era PLoS One 6 2011 e28512
44. J. Teichmann, U. Lange, T. Discher, J. Lohmeyer, H. Stracke, and R.G. Bretzel Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART) Eur J Med Res 14 2009 59 64
45. S. Bhasin, G.R. Cunningham, F.J. Hayes, A.M. Matsumoto, P.J. Snyder, and R.S. Swerdloff et al. Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline J Clin Endocrinol Metab 95 2010 2536 2559
46. E. Mylonakis, P. Koutkia, and S. Grinspoon Diagnosis and treatment of androgen deficiency in human immunodeficiency virus-infected men and women Clin Infect Dis 33 2001 857 864
47. I. Cassetti, J.V. Madruga, J.M. Suleiman, A. Etzel, L. Zhong, A.K. Cheng Study 903E Team The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients HIV Clin Trials 8 2007 164 172
48. H.J. Stellbrink, C. Orkin, J.R. Arribas, J. Compston, J. Gerstoft, E. Van Wijngaerden ASSERT Study Group Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study Clin Infect Dis 51 2010 963 967
49. Reynes J, Trinh R, Pulido F, Soto-Malave R, Gathe J, Qaqish R, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretoviral-naive subjects: 96-week results of the PROGRESS Study. AIDS Res Hum Retrovir. 2013;29:256-65.
50. G.A. McComsey, D. Kitch, E.S. Daar, C. Tierney, N.C. Jahed, and P. Tebas et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir-disoproxilfumarate- emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202 J Infect Dis 203 2011 1791 1801
51. H. Haskelberg, J.F. Hoy, J. Amin, P.R. Ebeling, S. Emery, A. Carr STEAL Study Group Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine PLoS ONE 7 2012 e38377
52. Martin A, Moore C, Mallon PWG, Hoy J, Emery S, Belloso W, et al. Bone mineral density in HIV participants randomized to raltegravir and lopinavir compared with standard second line therapy. AIDS 2013 (published ahead of print).
53. Wohl D, Bhatti L, Small CB, Edelstein H, Zhao H, Margolis D, et al. Simplification to abacavir/lamivudine + atazanavir from tenofovir/emtricitabine + ATV/ritonavir maintains viral suppression and improves bone biomarkers. 52nd Interscience Conference on Antimicrobials and Chemotherapy (ICAAC).September 9-12, 2012. San Francisco. Abstract H-556c.
54. Negredo E, Domingo P, Perez-Alvarez N, Gutierrez M, Puig J, Munoz J, et al. Multicenter Randomized Study to Assess Changes in HIV Subjects with Low Bone Mineral Density after Switching from Tenofovir to Abacavir: OsteoTDF Study (CROI 2013). Atlanta, GA. March 3-6, 2013. Abstract 824.
55. Bloch M, Tong W, Hoy J, Baker D, Richardson R, Carr A. Improved Low BMD and Bone Turnover Markers with Switch from Tenofovir to Raltegravir in Virologically Suppressed HIV-1+ Adults at 48 Weeks: The TROP Study. 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012). Seattle, WA. March 5-8, 2012. Abstract 878.
56. A. Curran, E. Martinez, M. Saumoy, L. del Rio, M. Crespo, and M. Larrousse et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy AIDS 26 2012 475 481
57. G. Guaraldi, G. Orlando, G. Madeddu, F. Vescini, P. Ventura, and S. Campostrini et al. Alendronate reduces boneresorption in HIV-associated osteopenia/osteoporosis HIV Clin Trials 5 2004 269 277
58. K. Mondy, W.G. Powderly, S.A. Claxton, K.H. Yarasheski, M. Royal, and J.S. Stoneman et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection J Acquir Immune Defic Syndr 38 2005 426 431
59. E. Negredo, E. Martínez-López, R. Paredes, J. Rosales, N. Pérez-Alvarez, and S. Holgado et al. Reversal of HIV-1-associated osteoporosis with once-weekly alendronate AIDS 19 2005 343 345
60. G.A. McComsey, M.A. Kendall, P. Tebas, S. Swindells, E. Hogg, and B. Alston-Smith et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV AIDS 21 2007 2473 2482
61. J. Huang, L. Meixner, S. Fernandez, and J.A. McCutchan A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis AIDS 23 2009 51 57
62. M.J. Bolland, A.B. Grey, A.M. Horne, S.E. Briggs, M.G. Thomas, and R.B. Ellis-Pegler et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial J Clin Endocrinol Metab 92 2007 1283 1288
63. D.M. Black, D.C. Bauer, A.V. Schwartz, S.R. Cummings, and C.J. Rosen Continuing bisphosphonate treatment for osteoporosis - for whom and for how long? N Engl J Med 366 2012 2051 2053
64. M.F. Holick, N.C. Binkley, H.A. Bischoff-Ferrari, C.M. Gordon, D.A. Hanley, and R.P. Heaney et al. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited J Clin Endocrinol Metab 97 2012 1153 1158
65. C.T. Longenecker, C.O. Hileman, T.L. Carman, A.C. Ross, S. Seydafkan, and T.T. Brown et al. Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial Antivir Ther 17 2012 613 621
66. J.P. Viard, J.C. Souberbielle, O. Kirk, J. Reekie, B. Knysz, and M. Losso et al. Vitamin D and clinical disease progression in HIV infection: Results from the EuroSIDA study AIDS 25 2011 1305 1315
67. P.L. Havens, K. Mulligan, R. Hazra, P. Flynn, B. Rutledge, M.D. van Loan Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 Study Team Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection J Clin Endocrinol Metab 97 2012 4004 4013
68. N. Binkley, D. Gemar, J. Engelke, R. Gangnon, R. Ramamurthy, and D. Krueger et al. Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults J Clin Endocrinol Metab 96 2011 981 988
69. F. Foissac, J.M. Tréluyer, J.C. Souberbielle, H. Rostane, S. Urien, and J.P. Viard Vitamin D3 supplementation scheme in HIV-infected patients based upon pharmacokinetic modelling of 25-hydroxycholecalciferol Br J Clin Pharmacol 75 2013 1312 1320
70. K.D. Cashman, K.M. Seamans, A.J. Lucey, E. Stöcklin, P. Weber, and M. Kiely et al. Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults Am J Clin Nutr 95 2012 1350 1356
71. A. Conesa-Botella, E. Florence, L. Lynen, R. Colebunders, J. Menten, and R. Moreno-Reyes Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen AIDS Res Ther 7 2010 40
72. T. Welz, K. Childs, F. Ibrahim, M. Poulton, C.B. Taylor, and C.F. Moniz et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase AIDS 24 2010 1923 1928